The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of stem cell signaling pathways in long-term responders (LR) versus primary refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under sunitinib (SU) treatment (SULONG study).
Javier Puente
No relevant relationships to disclose
Nuria Laínez
No relevant relationships to disclose
María José Méndez-Vidal
No relevant relationships to disclose
Emilio Esteban
No relevant relationships to disclose
Daniel E. Castellano
No relevant relationships to disclose
Laura Basterretxea
No relevant relationships to disclose
María José Juan Fita
No relevant relationships to disclose
Luis Antón Aparicio
No relevant relationships to disclose
Luis León Mateos
No relevant relationships to disclose
Julio Jose Lambea- Sorrosal
No relevant relationships to disclose
Begoña Perez-Valderrama
No relevant relationships to disclose
Sergio Vazquez-Estevez
No relevant relationships to disclose
Cristina Suárez
No relevant relationships to disclose
Xavier Garcia del Muro
No relevant relationships to disclose
Enrique Gallardo
No relevant relationships to disclose
Pablo Maroto
No relevant relationships to disclose
Maria Victoria Bolós
Employment or Leadership Position - Pfizer
Marina Morán
Employment or Leadership Position - Pfizer
Julian Sanz
No relevant relationships to disclose